Literature DB >> 16912566

Screening for colorectal cancer in Uruguay with an immunochemical faecal occult blood test.

Eduardo Fenocchi1, Luz Martínez, Julio Tolve, Daniel Montano, Mariella Rondán, Adolfo Parra-Blanco, Yoshinobu Eishi.   

Abstract

An observational prospective study was carried out in Uruguay to evaluate the feasibility of colorectal cancer screening using immunochemical faecal occult blood tests with no dietary restrictions in an average-risk population. An automated system was used for processing the samples with a cut-off haemoglobin level of 100 ng/ml. Of the 11,734 study participants who received an immunochemical test kit (OC-Hemodia), 10,573 (90.1%) returned samples for screening. The results of 1170 (11.1%) of the responders were positive. Subsequently, colonoscopy was performed on 879 (75.1%) of the participants with a positive test result and showed neoplasia in 330 participants. Fifty four had advanced cancer, 47 had early cancer, 131 had high-risk adenoma and 98 had low-risk adenoma. The detection rates and the positive predictive values were 0.95 and 8.6% for cancer, and 1.24 and 11.2% for high-risk adenoma, respectively. The high compliance and high detection rates for cancer and high-risk adenoma achieved in the colorectal cancer screening programme verifies the feasibility of an immunochemical faecal occult blood test in screening an average-risk population in Uruguay, a country with a small population, but with high morbidity and mortality rates for this disease.

Entities:  

Mesh:

Year:  2006        PMID: 16912566     DOI: 10.1097/00008469-200610000-00002

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  9 in total

1.  Performance of the fecal immunochemical test is not decreased by high ambient temperature in the rapid return system.

Authors:  Jae Myung Cha; Joung Il Lee; Kwang Ro Joo; Hyun Phil Shin; Jae Jun Park; Jung Won Jeun; Jun Uk Lim; Sang-Hyun Hwang
Journal:  Dig Dis Sci       Date:  2012-03-27       Impact factor: 3.199

2.  Uptake and positive predictive value of fecal occult blood tests: A randomized controlled trial.

Authors:  Jessica Chubak; Andy Bogart; Sharon Fuller; Sharon S Laing; Beverly B Green
Journal:  Prev Med       Date:  2013-09-09       Impact factor: 4.018

3.  Use of a low cut-off value for the fecal immunochemical test enables better detection of proximal neoplasia.

Authors:  Jae Myung Cha; Joung Il Lee; Kwang Ro Joo; Hyun Phil Shin; Jung Won Jeun; Jun Uk Lim
Journal:  Dig Dis Sci       Date:  2013-08-04       Impact factor: 3.199

4.  Circulating tumour markers can define patients with normal colons, benign polyps, and cancers.

Authors:  R Mead; M Duku; P Bhandari; I A Cree
Journal:  Br J Cancer       Date:  2011-06-28       Impact factor: 7.640

Review 5.  Strategies for prevention of gastrointestinal cancers in developing countries: a systematic review.

Authors:  Ahmad Zia Shams; Ulrike Haug
Journal:  J Glob Health       Date:  2017-12       Impact factor: 4.413

6.  Clinical impact of the immunochemical fecal occult blood test for colorectal cancer screening in Brazil.

Authors:  Cláudio R Teixeira; Michele L Bonotto; Júlio P Lima; Luciana F Figueiredo; Leonardo Conrado; Carlos Frasca
Journal:  Ann Gastroenterol       Date:  2017-04-27

7.  Cutoff value determines the performance of a semi-quantitative immunochemical faecal occult blood test in a colorectal cancer screening programme.

Authors:  L G M van Rossum; A F van Rijn; R J F Laheij; M G H van Oijen; P Fockens; J B M J Jansen; A L M Verbeek; E Dekker
Journal:  Br J Cancer       Date:  2009-09-15       Impact factor: 7.640

8.  Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea.

Authors:  Dae Ho Kim; Jae Myung Cha; Min Seob Kwak; Jin Young Yoon; Young-Hak Cho; Jung Won Jeon; Hyun Phil Shin; Kwang Ro Joo; Joung Il Lee
Journal:  Gut Liver       Date:  2018-03-15       Impact factor: 4.519

9.  Faecal immunochemical test-based colorectal cancer screening in Mexico: an initial experience.

Authors:  José María Remes-Troche; Gabriela Hinojosa-Garza; Priscilla Espinosa-Tamez; Arturo Meixueiro-Daza; Peter Grube-Pagola; Katherine Van Loon; Michael B Potter; Martin Lajous
Journal:  Fam Pract       Date:  2020-07-23       Impact factor: 2.290

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.